NurExone Biologic Inc. (NRX V) stock market data APIs
C$0.6981
0(0%)
as of June 30, 2025
Try our APIs with
free plan!
NurExone Biologic Inc. Financial Data Overview
Price chart is built with
Anychart
NurExone Biologic Inc., a pharmaceutical technology company, develops a platform for biologically guided exosome-based therapies for the treatment of central nervous system injuries. It develops and commercializes the ExoTherapy platform for production of exosome-loaded nanodrugs. The company is also developing an off-the-shelf, non-invasive, and novel treatment for the reversal or reduction of paralysis caused by spinal cord injury using membrane-bound extracellular vesicles technology, as well as to treat traumatic brain injuries and other neurological conditions. Its technology includes ExoPTEN for the treatment of acute spinal cord injury and glaucoma; and Exosomes as a drug delivery system for regeneration and healing of specific tissues. The company was founded in 2020 and is based in Toronto, Canada.
Prev. Close
0.6981
Open
0.6981
High
0.6981
Low
0.6981
52 wk Range
0.52-0.83
Market Cap
54 606 K
Shares Outstanding
78 008 K
EPS
-0.02
Beta
-0.031
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get NurExone Biologic Inc. data using free add-ons & libraries
Get NurExone Biologic Inc. Fundamental Data
NurExone Biologic Inc. Fundamental data includes:
- Net Revenue:
- EBITDA: -5 703 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-05-27
- EPS/Forecast: -0.02
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
NurExone Biologic Inc. News
New
NurExone Biologic Extends Spinal Cord Injury Therapy Portfolio With New RNA Sequences Promoting Healing and Regeneration
TORONTO and HAIFA, Israel, Nov. 29, 2023 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (FSE: J90) (NRX.V) (the “Company” or “NurExone”) has recently unveiled laboratory tests of its...
NurExone Reports Third Quarter 2023 Financial Results and Provides Corporate Update
TORONTO and HAIFA, Israel, Nov. 24, 2023 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (FSE: J90) (NRX.V) (the “Company” or “NurExone”), a pioneering biotechnology company, released...
NurExone Biologic Receives FDA Orphan-Drug Designation, Accelerating Development of ExoPTEN therapy for Acute Spinal Cord Injury Treatment
TORONTO and HAIFA, Israel, Oct. 30, 2023 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (FSE: J90) (NRX.V) (the “Company” or “NurExone”), a pioneering biotechnology company, is thril...
Appointment of Professor Teo Forcht Dagi to Scientific Advisory Board and Advisory Committee
TORONTO and HAIFA, Israel, Oct. 19, 2023 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (FSE: J90) (NRX.V) (the “Company” or “NurExone”), a biopharmaceutical company developing biolo...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
